Latest Obagi Medical Products (OMPI) Headlines
Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products
Marketwire - Wed Jan 29, 6:46AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) announced today the formal execution of the global exclusive licensing agreement with Obagi Medical Products (Obagi) for the commercialization of skin lightening compound TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products.
Suneva Medical Announces An Expansion Of Its ReGenica® Distribution Partnership With Obagi Medical Products
PR Newswire - Tue Oct 29, 7:00AM CDT
Suneva Medical, Inc., a rapidly growing medical aesthetics company, announced today plans to expand its existing partnership with Obagi Medical Products, Inc. (Obagi).
Medicinal and Botanical Manufacturing Industry - 2013 Edition Profiles Players such as Endo Pharmaceuticals Holdings Inc., Herbalife Ltd. and Landec Corporation
M2 - Thu May 23, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z8sq8r/medicinal_and) has announced the addition of Supplier Relations US, LLC's new report "Medicinal and Botanical Manufacturing Industry in the U.S. and its International Trade [2013 Edition]" to their offering. This 2013 publication of Medicinal and Botanical Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 175 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report conta
62.9% Return Seen to Date on SmarTrend Obagi Medical Products Call (OMPI)
Comtex SmarTrend(R) - Tue May 07, 10:52AM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 2 months, Obagi Medical Products has returned 62.91% as of today's recent price of $23.98.
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
CNW Group - Thu Apr 25, 7:02AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes).
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
CNW Group - Tue Apr 23, 7:02AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced it has extended the expiration date of the tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp., for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes). The offer and withdrawal rights described in the offering documents have been extended and will now expire at 12:00 midnight, New York City time, on Thursday, April 25, 2013 (which is one minute after 11:59 p.m. New York City time, on Wednesday, April, 24, 2013), unless the offer is further extended. The offer had previously been scheduled to expire at 12:00 midnight, New York City time, on Tuesday, April 23, 2013. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has indicated that as of the previously scheduled expiration, a total of 14,889,011 Obagi sha
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
CNW Group - Mon Apr 22, 7:01AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp. ("Purchaser"), for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Obagi expired at 11:59 p.m., New York City time April 19, 2013. The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.
Obagi Medical Products Up 62.8% Since SmarTrend Uptrend Call (OMPI)
Comtex SmarTrend(R) - Mon Apr 15, 5:06PM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 1 month, Obagi Medical Products has returned 62.77% as of today's recent price of $23.96.
The Zacks Analyst Blog Highlights: Safeway, Valeant Pharmaceuticals, Obagi Medical Products, Allergan and Avanir Pharmaceuticals
PR Newswire - Wed Apr 10, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Safeway (NYSE:SWY), Valeant Pharmaceuticals (NYSE:VRX), Obagi Medical Products, Inc. (Nasdaq:OMPI), Allergan, Inc. (NYSE::AGN) and Avanir Pharmaceuticals Ltd. (Nasdaq:AVNR).
Valeant: The Sole Suitor for Obagi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 09, 2:43PM CDT
Valeant Pharmaceuticals' (VRX) proposed acquisition of Obagi Medical Products, Inc. (OMPI) received a boost with Merz Pharma Group opting out of the race to purchase Obagi. Merz's decision ended the bidding war between Valeant and itself.
This Bidding War Was a Bidding Skirmish
David Williamson, The Motley Fool - Motley Fool - Tue Apr 09, 2:16PM CDT
Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals and Merz over Obagi Medical Products and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has...
Merz Drops Out of Bidding for Obagi Medical
Rich Smith, The Motley Fool - Motley Fool - Mon Apr 08, 4:47PM CDT
And so it ends, not with a bang, but a whimper. On Monday, Germany's Merz Pharma gave up on its attempt to buy Obagi Medical Products away from initial bidder Valeant Pharmaceuticals . While lamenting that "Obagi was an opportunity...
Skechers, Lufkin, Penn Virginia are big movers
AP - Mon Apr 08, 4:05PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Obagi Medical Products Shares Up 62.6% Since SmarTrend's Buy Recommendation (OMPI)
Comtex SmarTrend(R) - Mon Apr 08, 11:45AM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 3 weeks, Obagi Medical Products has returned 62.64% as of today's recent price of $23.94.
Merz Pharma withdraws Obagi acquisition offer
By The Associated Press - AP - Mon Apr 08, 8:54AM CDT
German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker.
Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products
Marketwire - Wed Jan 29, 6:46AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) announced today the formal execution of the global exclusive licensing agreement with Obagi Medical Products (Obagi) for the commercialization of skin lightening compound TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products.
Suneva Medical Announces An Expansion Of Its ReGenica® Distribution Partnership With Obagi Medical Products
PR Newswire - Tue Oct 29, 7:00AM CDT
Suneva Medical, Inc., a rapidly growing medical aesthetics company, announced today plans to expand its existing partnership with Obagi Medical Products, Inc. (Obagi).
Medicinal and Botanical Manufacturing Industry - 2013 Edition Profiles Players such as Endo Pharmaceuticals Holdings Inc., Herbalife Ltd. and Landec Corporation
M2 - Thu May 23, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z8sq8r/medicinal_and) has announced the addition of Supplier Relations US, LLC's new report "Medicinal and Botanical Manufacturing Industry in the U.S. and its International Trade [2013 Edition]" to their offering. This 2013 publication of Medicinal and Botanical Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 175 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report conta
62.9% Return Seen to Date on SmarTrend Obagi Medical Products Call (OMPI)
Comtex SmarTrend(R) - Tue May 07, 10:52AM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 2 months, Obagi Medical Products has returned 62.91% as of today's recent price of $23.98.
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
CNW Group - Thu Apr 25, 7:02AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes).
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
CNW Group - Tue Apr 23, 7:02AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced it has extended the expiration date of the tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp., for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes). The offer and withdrawal rights described in the offering documents have been extended and will now expire at 12:00 midnight, New York City time, on Thursday, April 25, 2013 (which is one minute after 11:59 p.m. New York City time, on Wednesday, April, 24, 2013), unless the offer is further extended. The offer had previously been scheduled to expire at 12:00 midnight, New York City time, on Tuesday, April 23, 2013. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has indicated that as of the previously scheduled expiration, a total of 14,889,011 Obagi sha
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
CNW Group - Mon Apr 22, 7:01AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Odysseus Acquisition Corp. ("Purchaser"), for all of the outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Obagi expired at 11:59 p.m., New York City time April 19, 2013. The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.
Obagi Medical Products Up 62.8% Since SmarTrend Uptrend Call (OMPI)
Comtex SmarTrend(R) - Mon Apr 15, 5:06PM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 1 month, Obagi Medical Products has returned 62.77% as of today's recent price of $23.96.
The Zacks Analyst Blog Highlights: Safeway, Valeant Pharmaceuticals, Obagi Medical Products, Allergan and Avanir Pharmaceuticals
PR Newswire - Wed Apr 10, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Safeway (NYSE:SWY), Valeant Pharmaceuticals (NYSE:VRX), Obagi Medical Products, Inc. (Nasdaq:OMPI), Allergan, Inc. (NYSE::AGN) and Avanir Pharmaceuticals Ltd. (Nasdaq:AVNR).
Valeant: The Sole Suitor for Obagi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 09, 2:43PM CDT
Valeant Pharmaceuticals' (VRX) proposed acquisition of Obagi Medical Products, Inc. (OMPI) received a boost with Merz Pharma Group opting out of the race to purchase Obagi. Merz's decision ended the bidding war between Valeant and itself.
This Bidding War Was a Bidding Skirmish
David Williamson, The Motley Fool - Motley Fool - Tue Apr 09, 2:16PM CDT
Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals and Merz over Obagi Medical Products and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has...
Merz Drops Out of Bidding for Obagi Medical
Rich Smith, The Motley Fool - Motley Fool - Mon Apr 08, 4:47PM CDT
And so it ends, not with a bang, but a whimper. On Monday, Germany's Merz Pharma gave up on its attempt to buy Obagi Medical Products away from initial bidder Valeant Pharmaceuticals . While lamenting that "Obagi was an opportunity...
Skechers, Lufkin, Penn Virginia are big movers
AP - Mon Apr 08, 4:05PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Obagi Medical Products Shares Up 62.6% Since SmarTrend's Buy Recommendation (OMPI)
Comtex SmarTrend(R) - Mon Apr 08, 11:45AM CDT
SmarTrend identified an Uptrend for Obagi Medical Products (NASDAQ:OMPI) on March 15th, 2013 at $14.72. In approximately 3 weeks, Obagi Medical Products has returned 62.64% as of today's recent price of $23.94.
Merz Pharma withdraws Obagi acquisition offer
By The Associated Press - AP - Mon Apr 08, 8:54AM CDT
German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker.
